ANCON Medical specializes in the development of Nanoparticle Biomarker Tagging (NBT) technology, which offers a simple breath screening device with unparalleled sensitivity. The company has an impressive portfolio of patents and intellectual property in the U.S. and U.K. Their technology is designed for point-of-care clinics, providing early detection capabilities for life-threatening illnesses like lung cancer and tuberculosis. ANCON Medical has received grants and awards from public bodies and has recently demonstrated the potential of NBT technology in diagnosing tuberculosis and lung cancer. With facilities in Minnesota (USA) and Kent (UK), the company is a leading player in the medical device manufacturing community and collaborates with global market leaders and renowned laboratories.